Clinical Trial Update: EC17 for Intraoperative Imaging in Occult Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating EC17 as an intraoperative imaging agent for detecting occult ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• EC17 (folate-hapten conjugate)

Snippet

Sponsor: University of Pennsylvania | Conditions: Ovarian Cancer | Phase 1 | Status: COMPLETED